VIKING THERAPEUTICS INC (VKTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$25.79-7.79%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · VKTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -70.4% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
VKTX — earnings miss
Dated 2026-10-28
of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Why it matters: Part 2 tests daily oral and less-frequent shot options after weight-loss treatment. Results can show whether these choices help maintain weight loss.
Supportive ifThe company starts Part 2 and later reports weight loss held near the level reached before the switch to maintenance dosing.
Worry ifPart 2 is delayed, stopped, or reports that weight loss falls sharply after the switch to maintenance dosing.
Why it matters: Viking reported $960 million in cash after stock and note offerings. High trial costs make cash levels important to track.
Worry ifA later report shows cash under $500 million, or says the company will issue more stock or debt before key trial results.
Less concerning ifCash remains near or above $900 million, with no new large financing before the next major trial update.
Why it matters: VK3019 is a second obesity drug program. A 28-day study would move it beyond single-dose testing.
Supportive ifThe company starts the 28-day multiple ascending dose study in the first quarter of 2027, as planned.
Worry ifThe study has not started by the end of the first quarter of 2027, or the company reports a pause.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$223 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $572 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,254 loss on $10,000 · 42.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.